AI-based software for digital drug testing

Project Information

EYESCANNER

Grant agreement ID: 190138223

DOI

10.3030/190138223

Project closed

EC signature date 14 April 2023

Start date 1 April 2023

End date 31 March 2025

Funded under

• The European Innovation Council (EIC)

Total cost

€ 3 509 678,75

EU contribution

€ 2 456 775,00

Coordinated by

SIGHTIC ANALYTICS AB
Sweden

Periodic Reporting for period 2 - EYESCANNER (AI-based software for digital drug testing)

Reporting period: 2024-04-01 to 2025-03-31

Summary of the context and overall objectives of the project

Drug consumption is rising worldwide. In Europe, alcohol and other narcotic drugs cause 30% of all road deaths, 25% of all fatal workplace accidents, and >54% of all e-scooter accidents. We believe that most of these accidents could be prevented using the right tools.
To this aim, we have developed EYESCANNER, a revolutionary AI-based software that detects the influence of alcohol and other drugs through image analysis of the eye-area.
EYESCANNER is a versatile digital tool that can use existing tech infrastructure: smart phones, integrated into cars, hospital equipment, etc. Our solution offers a drug test for environments where drug testing was not possible (e.g. cars, e-scooter apps) and a better alternative to currently used methods (i.e. law enforcement, corporate, healthcare).
This project includes 3 main objectives:
1) The completion of a validation of study.
2) The development of the production version of our software.
3) Testing the usability of the beta version of EYESCANNER in real life scenarios, starting with the automotive and micro mobility sectors, and partnering with industry leaders.
With the implementation of this project, we have finalised EYESCANNER development and demonstrated its application on different scenarios, to make EYESCANNER the global leader for digital drug-testing.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

EYESCANNER project has developed an advanced, AI-powered eye-tracking solution for innovative drug detection.

During the project the following actions have been completed:
WP1 – The preparatory work and plan for the validation study has been carried out.
WP2 – The production version of the Eyescanner solution has been developed, including the software and secure data acquisition.
WP3 – The first pilot studies for testing and validation have been developed, including analyses on the requirements & integration for vehicles and micro-mobility, significantly improving the solution and facilitating the customer-integration.
WP4 – The pre-commercial actions have been successfully implemented, including communication & dissemination activities and engagement with relevant stakeholders.
WP5 – A comprehensive project management strategy has been established and effectively implemented with satisfactory results.
WP6 – The ethics requirements have been regularly addressed with the support of the appointed Ethics Board.

The work developed along the project implementation has allowed to achieve the expected results:
- The validation of study was successfully completed.
- The production version of EYESCANNER software was developed.
- The usability of the beta version of EYESCANNER is tested in real life scenarios, starting with the automotive and micro mobility sectors.
After the completion of the Project work plan, EYESCANNER solution is ready for the subsequent commercial stage.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Drug-detection methods and prevention measures have barely improved for several decades, creating a pressing needs such as: a) companies looking for measures to create a safe working environment, increase productivity, and prevent job fatalities and accident-related absences; b) automotive firms and mobility companies wanting to offer safety systems able to prevent drug-induced accidents; c) law enforcement agencies who lack fast and reliable methods to detect drug use; d) the healthcare system needing to reduce costs and medical waste.
EYESCANNER solves all these needs, and we believe that our solution has an exclusive place in the market: we have developed a unique AI-based software technology that uses eye-movement patterns to predict whether a person is under the influence of alcohol and other narcotics drugs. Our uniqueness relies on the combination of proprietary and very extensive medical drug tests data repository combined with modern image analysis and deep learning techniques.
The implementation of this project has allowed the completion of EYESCANNER solution, including validation, software optimisation, testing the usability in real-conditions and access to further finance for commercialisation & market uptake.
Our solution will revolutionize the global drug screening market, allowing a wide application of our technology with the potential to change the field of drug testing. Our strong know-how, expertise and network of key partners will enable our establishment as the global leader in digital drug screening.

IMAGE 2 - EYESCANNER